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Abstract: Iron deficiency may alter dopaminergic transmission in the brain. This study investigated 16 
whether iron metabolism is associated with negative symptoms in patients with first-episode 17 
psychosis. The study enrolled 121 patients with first-episode schizophrenia spectrum disorder, 18 
whose duration of treatment was 2 months or less. Negative symptoms were measured using the 19 
Positive and Negative Syndrome Scale (PANSS) and Clinician-Rated Dimensions of Psychosis 20 
Symptom Severity (Dimensional) scale of the DSM-5. Prominent negative symptoms were defined 21 
as moderate or severe negative symptoms on the Dimensional scale of the DSM-5. Iron deficiency 22 
was defined as a serum ferritin ≤20 ng/mL. Patients with iron deficiency were significantly more 23 
likely to have prominent negative symptoms (45.2 vs. 22.2%;p=0.014) and a higher PANSS negative 24 
symptoms score (p=0.046) than those with normal ferritin levels. Patients with prominent negative 25 
symptoms had significantly lower ferritin levels (p=0.025). The significance of these results 26 
remained after controlling for the duration of illness and other confounding variables. Our finding 27 
of an independent association between iron deficiency and negative symptoms in patients at the 28 
very early stage of illness implies that iron dysregulation has an effect on negative symptoms in 29 
patients with schizophrenia. The possibility of therapeutic intervention with iron should be further 30 
investigated. 31 
Keywords: schizophrenia; psychosis; iron; ferritin; negative symptom; first-episode 32 
 33 
1. Introduction 34 
Schizophrenia is a severe mental illness that typically begins in adolescence or early adult life 35 
and is often chronic and disabling. Although delusions and hallucinations are the typical symptoms 36 
seen at the time of diagnosis, negative symptoms such as avolition or diminished emotional 37 
expression are more persistent core symptoms. The revised dopamine hypothesis, i.e., prefrontal 38 
hypodopaminergia, is one of the most influential theories regarding the etiology of schizophrenia [1]. 39 
Generally, the prefrontal dopamine system suppresses the limbic dopamine system; however, in 40 
patients with schizophrenia, this suppression seems to be reduced due to disrupted prefrontal 41 
dopaminergic activity, leading to elevated limbic dopaminergic activity. Additionally, prefrontal 42 
hypodopaminergia is concordant with negative symptoms of schizophrenia [2].  43 
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Iron is an essential trace element for nearly all living organisms and is a component of 44 
hemoglobin, which is vital for the delivery and storage of oxygen [3]. Iron is also required for cell 45 
viability, as it is a constituent of proteins involved in DNA synthesis, cell proliferation, and energy 46 
metabolism [4]. Furthermore, iron is the most abundant transition metal in the brain, and is vital for 47 
a number of neurological functions including neurotransmitter synthesis, myelination of neurons, 48 
mitochondrial function, and electron transfer [5-7]. Therefore, a sufficient iron supply is necessary for 49 
neurodevelopmental processes [8]; in fact, reductions in the iron supply at several stages of 50 
development result in long-term changes in monoamine neurotransmission that outlast the iron 51 
deficient periods [9-11]. Conversely, iron overload can cause cellular toxicity and neuronal damage 52 
via free radical formation and peroxidation of lipid membranes [3,12]. Iron accumulates as the brain 53 
ages and may be linked to motor and cognitive dysfunction in the elderly [6].  54 
Iron homeostasis is essential for the integrity of the brain monoaminergic system [13], and its 55 
dysregulation has been reported to be involved in neuropsychiatric disorders associated with 56 
dopamine, such as attention deficit hyperactivity disorder and Tourette syndrome [14-17], and 57 
neurological movement disorders such as restless legs syndrome (RLS) and Parkinson’s disease, 58 
which are associated with reduced central dopamine activity [18]. In patients with RLS, the levels of 59 
iron and ferritin in serum or cerebrospinal fluid are significantly reduced [18-20]. Ferritin levels were 60 
also reported to be positively correlated with central nervous system (CNS) dopamine levels in 61 
Parkinson’s disease [21].  62 
In previous animal studies, induced iron deficiency has been reported to alter both 63 
dopaminergic and serotoninergic transmission in the brain [22]. This iron-dopamine interaction 64 
might therefore conceivably account for symptoms in patients with schizophrenia. Some evidence 65 
suggests a role for iron deficiency in chronic and tardive akathisia, which are associated with reduced 66 
dopamine activity due to the use of dopamine antagonists. Results from previous studies 67 
investigating the association between akathisia and iron deficiency in patients with psychosis have 68 
been inconsistent; in patients with chronic psychotic disorders, akathisia was found to be associated 69 
with decreased plasma ferritin and iron levels [23-27], whereas no association between iron indices 70 
and akathisia was observed in other studies of chronic and acute akathisia [28-31].  71 
In some studies, decreased serum iron levels has been observed in catatonic and acutely 72 
psychotic presentations [32-33]. However, compared with other psychiatric and neurological 73 
disorders related to dopamine neurotransmission, there is a lack of evidence for a role of iron 74 
metabolism in the psychopathology of patients with first-episode schizophrenia. Recently, it was 75 
shown that iron depletion in monkeys disrupted both dopaminergic and serotoninergic transmission 76 
in various CNS regions, including the striatum and prefrontal cortex [13]. Therefore, negative 77 
symptoms in schizophrenia might potentially be attributed at least in part to brain iron homeostasis 78 
breakdown, which has a widespread effect on the monoaminergic system. However, to our 79 
knowledge, no investigation has focused on the association between iron metabolism and negative 80 
symptoms associated with prefrontal hypodopaminergic state in patients with first-episode 81 
schizophrenia. 82 
Iron depletion occurs in the brain before it occurs in red blood cells during progressive negative 83 
iron balance [34]. So, a latent iron deficiency state may cause depletion of brain tissue without 84 
depleting red blood cells [35]. In this study, we hypothesized that iron dysregulation may be 85 
associated with negative symptoms of schizophrenia spectrum disorder. Specifically, we investigated 86 
the associations of serum iron and related variables, including ferritin levels, with negative symptoms 87 
in patients with first-episode psychosis. Ferritin is of particular utility as a primary marker of iron 88 
metabolism because it regulates the binding and storage of iron and plays an important role in 89 
maintaining iron metabolism homeostasis and regulating iron content in the brain. 90 
2. Methods 91 
2.1. Study population 92 
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We analyzed data from an early psychosis cohort assembled at Gwangju, Republic of Korea 93 
(Gwangju Early Treatment and Intervention Team; GETIT study). The GETIT cohort included 94 
patients whose duration of treatment for psychotic symptoms was ≤ 2 years and who met the criteria 95 
for ‘schizophrenia spectrum disorder and other psychotic disorders’ according to the Diagnostic and 96 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [36]. Inclusion criteria for this study 97 
were a first episode of schizophrenia, schizophreniform disorder, or other specified schizophrenia 98 
spectrum disorder and duration of treatment ≤ 2 months to minimize the confounding effects of 99 
illness on iron metabolism. Exclusion criteria were age less than 18 years and diagnosis of a 100 
substance- or medication-induced psychotic disorder, psychotic disorder due to another medical 101 
condition, or severe neurological or medical disorders. This study was conducted from September 102 
2015 to August 2018 and was approved by the Chonnam National University Hospital Institutional 103 
Review Board. All subjects provided written informed consent before participation.  104 
2.2. Sociodemographic and clinical data 105 
The baseline data included age, sex, diagnosis, type of antipsychotics taken, duration of 106 
treatment, and duration of untreated psychosis (DUP), which was defined as the time between the 107 
appearance of the first psychotic symptoms and the start of appropriate antipsychotic treatment [37].  108 
Psychopathology including negative symptoms was measured by the Positive and Negative 109 
Syndrome Scale (PANSS) [38,39]. We used the five factors of the PANSS; positive, negative, 110 
depressive, cognitive, and excited factors [40]. Additionally, prominent negative symptoms were 111 
defined as moderate or severe on the negative symptom dimension of the Clinician-Rated 112 
Dimensions of Psychosis Symptom Severity (Dimensional) scale in the DSM-5 [36]; moderate or 113 
severe decrease in facial expressivity, prosody, gestures, or self-initiated behavior. Calgary 114 
Depression Scale for Schizophrenia (CDSS) [41,42], and Social Occupational Functioning Assessment 115 
Scale (SOFAS) [43]. All raters were trained psychiatrists and were certified to rate the PANSS. - The 116 
dietary habits of patients were measured using a 20 item self-administered questionnaire based on 117 
dietary guidance published by the Korean Ministry of Health and Welfare [44]. The dietary 118 
questionnaire consists of three subcategories, including five items for diet regularity (e.g., regular 119 
diet, breakfast every morning, appropriate amounts), six items for a balanced diet (e.g., dairy foods, 120 
fruits, vegetables), and nine items for an unhealthy diet and habits (e.g., instant food, fatty foods, 121 
salty foods, caffeine-containing foods). Each item was scored on three Likert scales (1, 3, and 5 points) 122 
according to the frequency of the dietary habit. Higher scores indicate better dietary habits in each 123 
category.  124 
2.3. Laboratory measures 125 
Fasting venous blood was drawn in the morning of the assessment day. The iron parameters 126 
measured comprised serum ferritin, iron, total iron binding capacity (TIBC), transferrin saturation 127 
(iron/TIBC), and hemoglobin levels. We used ferritin, as a key measure of iron status, to predict 128 
negative symptoms. In this study, latent iron deficiency was defined as a serum ferritin ≤ 20 ng/mL 129 
[45,46]. 130 
2.4. Statistical analyses 131 
Demographic and clinical characteristics were compared according to the presence of iron 132 
deficiency defined by a serum ferritin ≤ 20 ng/mL and prominent negative symptoms, using the chi-133 
square test, independent t-test, and Mann–Whitney U-test, as appropriate. The difference in PANSS 134 
scores for negative factors between the two groups according to iron deficiency was compared using 135 
analysis of covariance (ANCOVA) after adjusting for other significant variables (i.e., those with 136 
statistical significance in the univariate analyses and sex). Finally, logistic regression analysis was 137 
used to investigate associations between prominent negative symptoms and iron deficiency after 138 
adjusting for significant variables. Values that were not normally distributed were entered as 139 
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covariates after log transformation. All statistical tests were two tailed, and a P-value < 0.05 was 140 
considered to indicate statistical significance. All analyses were performed with IBM SPSS Statistics 141 
software version 23.0.    142 
3. Results 143 
The GETIT cohort enrolled 257 patients with psychosis for 3 years beginning in 2015. Of these, 144 
194 patients (75.5%) were in their first episode. After excluding subjects based on criteria regarding 145 
duration of treatment, age, and diagnosis, this study recruited 121 patients whose first-episode 146 
psychosis had been treated for 2 months or less. Seventy-three patients (60.3%) were female. The 147 
median (interquartile range, IQR) age of the participants was 27.0 (22.0–32.0) years. The median (IQR) 148 
duration of treatment and DUP were 1.0 (0.7–1.2) and 2.2 (1.0–12.0) months, respectively. Prominent 149 
negative symptoms were observed in 31 (25.6%) of patients, with no significant sex difference. Serum 150 
ferritin ≤ 20 ng/mL were observed in 34 (28.1%) patients and were very significantly more common 151 
in female patients (Table 1). Median serum ferritin and mean hemoglobin levels were significantly 152 
lower in female patients than in male patients [21.1 (12.7–47.8) ng/mL vs. 111.2 (77.2–165.5) ng/mL 153 
and 12.5 ± 1.4 g/dl vs. 14.7 ± 1.1 g/dl, respectively; both P-values < 0.001]. Transferrin saturation was 154 
also significantly lower in female patients than in male patients [24.1 ± 14.2 vs. 35.5 ± 15.1%; P-value < 155 
0.001].  156 
Table 1 compares the sociodemographic and clinical characteristics of the participants according 157 
to the presence of iron deficiency and prominent negative symptoms. Patients with ferritin level ≤ 20 158 
ng/mL with had significantly lower hemoglobin, iron, and transferrin saturation levels, and higher 159 
TIBC. Patients with low ferritin levels were significantly more likely to have prominent negative 160 
symptoms (45.2 vs. 22.2%; p-value = 0.014) and higher PANSS negative symptoms scores score (p-161 
value = 0.046) than those with normal ferritin levels. Patients with iron deficiency had a significantly 162 
shorter duration of treatment. Patients with prominent negative symptoms had significantly higher 163 
CDSS scores and PANSS negative, positive, depressive, cognitive, and total scores. They also had 164 
significantly lower SOFAS scores. Patients with prominent negative symptoms had significantly 165 
lower ferritin levels. The DUP was significantly longer and they were significantly less likely to 166 
receive inpatient service at the time of assessment.  167 
Figure 1 shows the results of the ANCOVA for differences in the PANSS negative symptom 168 
score according to the presence of iron deficiency after controlling for the confounding effects of sex, 169 
inpatient status, DUP, duration of treatment, and scores on the SOFAS, CDSS, and PANSS positive 170 
and cognitive factors. After controlling for these confounding factors, the PANSS negative symptoms 171 
score was significantly higher in patients with a ferritin level ≤ 20 ng/mL (p = 0.021). Logistic 172 
regression analyses also showed that prominent negative symptoms were independently associated 173 
with the low ferritin group [OR (95% CI) = 9.2 (1.8–47.0); p = 0.008] and log-transformed ferritin level 174 
[OR (95% CI) = 5.7 (1.1–29.8); p = 0.041), even after controlling for the above confounding variables.175 
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Table 1. Comparisons of sociodemographic and clinical characteristics according to the presence of iron deficiency and prominent negative symptoms. 176 
  Serum ferritin level   Prominent negative symptoms   
 
Total 
(N=121) 
≤ 20 ng/ml 
(N=34, 28.1%) 
> 20 ng/ml 
(N=87, 71.9%) 
Statistical 
value 
p-
value 
Yes 
(N=31, 25.6%) 
No 
(N=90, 74.4%) 
Statistical 
value 
p-
value 
Sociodemographic and clinical characteristics     
Age, Med, (IQR) year 
27.0 (22.0-
32.0) 
27.5 (22.8-
32.5) 
25.0 (21.0-32.0) U = -1.270 0.204 25.0 (20.0-30.0) 27.0 (22.0-32.5) U = -1.403 0.161 
Sex, female; N (%) 73 (60.3) 33 (45.2) 40 (54.8) χ2 = 26.653 < 0.001 21 (28.8) 52 (72.2) χ2 = 0.957 0.328 
DUP, Med. (IQR) Mo. 2.2 (1.0-12.0) 4.0 (1.0-24.0) 2.0 (1.0-11.0) U = -0.937 0.349 8.5 (1.1-25.0) 2.0 (1.0-7.3) U = -2.859 0.004 
Duration of Tx, Med. (IQR) Mo. 1.0 (0.7-1.2) 1.0 (0.5-1.0) 1.0 (0.8-1.5) U = -2.512 0.012 1.0 (0.8-1.2) 1.0 (0.6-1.2) U = -0.102 0.919 
Inpatient status, N (%) 71 (58.7) 17 (23.9) 54 (76.1) χ2 = 1.469 0.226 12 (16.9) 59 (83.1) χ2 = 6.854 0.009 
Diagnosis, N (%)  
Schizophrenia 
 
77 (63.6) 
 
21 (27.3) 
 
56 (72.7) 
χ2 = 0.240 0.887 
 
24 (31.2) 
 
53 (68.8) 
χ2 = 5.613 0.060 
Schizophreniform 32 (26.4) 10 (31.3) 22 (68.6)    7 (21.9) 25 (78.1)   
Other specified. 12 (9.9)  3 (25.0)  9 (75.0)    0 (0.0) 12 (100.0)   
Antipsychotics, N (%) 
Amisulpride 
 
32 (26.4) 
 
 8 (25.0) 
 
24 (75.0) 
χ2 = 6.843 0.233 
 
12 (37.5) 
 
20 (62.5) 
χ2 = 7.713 0.173 
Aripiprazole 21 (17.4) 10 (47.6) 11 (52.4)    2 (9.5) 19 (90.5)   
Paliperidone 53 (43.8) 14 (26.4) 39 (73.6)   15 (28.3) 38 (71.7)   
Risperidone  5 (4.1)  0 (0.0)  5 (100.0)    0 (0.0)  5 (100.0)   
Quetiapine  7 (5.8)  1 (14.3)  6 (85.7)    1 (14.3)  6 (85.7)   
None  3 (2.5)  1 (33.3)  2 (66.7)    1 (33.3)  2 (66.7)   
Laboratory measures     
Hemoglobin, mean (SD) g/dl 13.4 (1.7) 
12.5 (10.5- 
13.2) 
13.9 (13.1-14.9) t = -6.966 < 0.001 12.9 (2.2) 13.6 (1.4) t = -1.703 0.097 
Iron, Med. (IQR) μg/dl 90 (58-115) 51 (26-90) 100 (67-127) U = -4.671 < 0.001 73 (40-112) 91 (61-116) U = -1.416 0.157 
TIBC, Med. (IQR) μg/dl 326 (291-354) 360 (333-396) 310 (280-340) U = -4.994 < 0.001 338 (285-367) 325 (292-350) U = -1.146 0.252 
Transferrin Sat., mean (SD) % 28.6 (15.6) 16.8 (11.0) 33.2 (14.7) t = -5.908 < 0.001 25.8 (15.9) 29.5 (15.4) t = -1.138 0.257 
Ferritin, Med. (IQR) ng/ml 
48.7 (18.0-
105.5) 
12.4 (7.6-16.0) 
86.6 (43.7-
128.5) 
U = -8.529 < 0.001 29.3 (8.8-89.2) 
64.6 (20.9-
109.4) 
U = -2.238 0.025 
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Ferritin ≤ 20 ng/ml, N (%) 34 (28.1) Not applicable 14 (41.2) 20 (58.8) χ2 = 6.005 0.014 
Psychiatric measures     
PANSS, Positive, mean (SD) 16.0 (4.8) 16.7 (4.6) 15.7 (4.9) t = 1.031 0.305 19.2 (3.9) 14.8 (4.7) t = 4.682 < 0.001 
Negative, mean (SD) 18.6 (5.6) 20.3 (5.8) 18.0 (5.4) t = 2.021 0.046 23.7 (5.6) 16.9 (4.5) t = 6.809 < 0.001 
Cognitive, mean (SD) 14.4 (3.7) 14.3 (3.9) 14.5 (3.6) t = -0.222 0.825 15.8 (3.1) 13.9 (3.8) t = 2.439 0.016 
Depressive, mean (SD) 12.4 (3.7) 12.3 (3.3) 12.5 (3.8) t = -0.222 0.825 14.7 (3.3) 11.6 (3.5) t = 6.326 < 0.001 
Excited, mean (SD) 7.5 (3.0) 7.8 (3.1) 7.3 (3.0) t = 0.778 0.438 8.4 (3.6) 7.1 (2.7) t = 1.766 0.085 
Total, mean (SD) 68.8 (15.1) 71.2 (15.0) 67.8 (15.2) t = 1.112 0.268 81.6 (12.5) 64.3 (13.4) t = -5.833 < 0.001 
Prominent negative Sx, N (%) 31 (25.6) 14 (45.2) 17 (54.8) χ2 = 6.005 0.014 Not applicable 
SOFAS, mean (SD) 58.2 (10.2) 56.9 (9.7) 58.7 (10.4) t = -0.872 0.385 50.4 (10.8) 60.9 (8.5) t = -5.550 < 0.001 
CDSS, mean (SD) 4.5 (4.0) 4.2 (3.8) 4.6 (4.1) t = -0.484 0.629 7.3 (4.7) 3.6 (3.3) t = 4.063 < 0.001 
Diet habit,  
Regular diet, mean (SD) 
 
17.0 (6.5) 
 
17.1 (6.7) 
 
17.0 (6.5) 
 
t = 0.126 
 
0.900 
 
16.1 (6.4) 
 
17.3 (6.6) 
 
t = -0.904 
 
0.368 
Balanced diet, mean (SD) 18.2 (6.8) 18.7 (7.4) 18.0 (6.6) t = 0.490 0.625 18.2 (6.8) 18.2 (6.9) t = 0.016 0.987 
Healthy diet, mean (SD) 31.8 (6.3) 32.0 (5.6) 31.8 (6.6) t = 0.168 0.867 31.6 (6.0) 31.9 (6.4) t = -0.241 0.810 
Med. Median; IQR, Interquartile Range; SD, Standard Deviation; Mo., month; DUP, Duration of Untreated Psychosis; PANSS, Positive and Negative Syndrome Scale; SOFAS, Social 177 
Occupational Functioning Assessment Scale; CDSS, Calgary Depression Scale for Schizophrenia; Tx, treatment; Sx, symptom; Sat. saturation 178 
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Figure 1. Adjusted mean (95% confidence interval) of Positive And Negative Syndrome Scale 180 
(PANSS) negative factor score according to iron deficiency. Adjustment for sex, inpatient status, 181 
duration of untreated psychosis, duration of treatment, and scores on the Social Occupational 182 
Functioning Assessment Scale, Calgary Depression Scale for Schizophrenia, and PANSS positive and 183 
cognitive factors. F = 5.471, p-value = 0.021. 184 
4. Discussion 185 
Among the patients with first-episode psychosis, those with latent iron deficiency defined by a 186 
low serum ferritin level had significantly more severe negative symptoms. The association between 187 
iron status and negative symptoms was still significant after controlling for the duration of illness 188 
and other confounding variables. These results support our hypothesis that abnormal iron 189 
metabolism decreases dopaminergic activity and is consequently associated with negative 190 
symptoms. To the best of our knowledge, this is the first study to investigate an association between 191 
iron dysregulation and negative symptoms in first-episode schizophrenia spectrum disorder.  192 
The association of interest between iron status and negative symptoms was derived from an 193 
analysis of cross-sectional data; therefore the direction of causation cannot be concluded with 194 
certainty. Specifically, it is possible that iron depletion is a cause of negative symptoms, as will be 195 
considered further, or that negative symptoms cause iron depletion. In patients with chronic 196 
psychotic disorders, iron deficiency may be attributed to behaviors such as poor nutritional intake, 197 
in turn due to psychotic disorders, or to environmental factors such as long-term hospitalization. 198 
However, the effects of chronic psychotic experiences on iron status might not be critical because all 199 
participants in this analysis were experiencing the first episode of psychosis and their illness was at 200 
a very early stage. In addition, eating patterns and behaviors did not differ significantly according to 201 
the presence of iron deficiency and prominent negative symptoms. Therefore, the effect of mental 202 
disorders on general diet quality might not be significant.  The fact that statistical significance 203 
remained after controlling for DUP, a potential factor mediating the association between iron status 204 
and negative symptoms, also suggests that iron metabolism may predict negative symptoms, and 205 
may not be a consequence of psychotic symptoms in patients with schizophrenia.  206 
Negative symptoms have been found to be associated with reduced dopamine activity [2] and 207 
it is possible that iron deficiency might act to increase the likelihood of these symptoms through a 208 
range of possible mechanisms. First, iron is a co-factor of tyrosine hydroxylase, which acts as the rate-209 
limiting enzyme in dopamine synthesis [47]. Therefore, reduced brain iron levels would be expected 210 
20.2
18.0 
0
5
10
15
20
PANSS negative factor
Ferritin ≤ 20 ng/ml Ferritin > 20 ng/ml
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to reduce the availability of iron in dopamine neurons, which may in turn reduce dopamine activity 211 
in the CNS.  212 
Second, iron depletion has been found to mimic dopamine type 2 (D2) receptor blockade in 213 
numerous animal models [23], It has been hypothesized that iron deficiency may alter D2 receptor 214 
function, because iron is part of the D2 receptor. Additionally, it has been suggested that, as the D2 215 
receptor is an iron-containing protein, low serum iron levels result in hypofunctionality of D2 216 
receptors, which predisposes patients with schizophrenia to akathisia and negative symptoms [27,48, 217 
49]. Some studies have reported that nutritional iron deficiency alters dopaminergic 218 
neurotransmission, increasing the concentration of extracellular dopamine and reducing the activity 219 
of dopamine transporters and D2 receptors in the striatum [50], an essential integrative node in the 220 
dopamine transmission pathway, and striatal dopaminergic dysfunction has been linked to cortical 221 
dopaminergic dysregulation [51]. Iron deficiency may therefore be linked to cortical dopamine 222 
dysregulation, which may cause negative symptoms in schizophrenia.  223 
Third, hypoferremia, a cytokine-mediated reduction of circulating non-heme iron in the blood, 224 
is a common response to systemic infections or generalized inflammatory disorders. Inflammation-225 
induced hypoferremia may disrupt brain development, leading to functional defects in adulthood 226 
that are synonymous with psychiatric disorders such as schizophrenia 8, [50]. An emerging literature 227 
provides evidence that gestational exposure to infection contributes to the etiology of schizophrenia 228 
[53]. During prenatal inflammation, hypoferremia plays a fundamental role in the developmental 229 
effects of this maternal insult to mesolimbic dopamine function [8].  230 
Several previous studies of the general population have observed a relationship between low 231 
iron status and mood, indicating a potential role for iron in the development of mild depressive 232 
symptoms [54-56]. In other studies of the geriatric population or stroke patients, high iron levels were 233 
associated with depression. In this study, however, we observed no relationship between iron status 234 
and depression in patients with schizophrenia.  235 
Negative symptoms are a significant barrier to successful functional outcomes and recovery in 236 
individuals with schizophrenia [57]. However, currently available treatments for negative symptoms 237 
appear to confer only modest benefits [58]. A study reported akathisia in a patient with iron 238 
deficiency that had not responded to standard interventions, but responded dramatically to 239 
intravenous iron treatment [59]. Therefore, longitudinal research is needed to clarify the relationship 240 
between negative symptoms of schizophrenia and iron status, and the possibility of therapeutic 241 
intervention should also be investigated. 242 
Several limitations should be considered when interpreting our results.  First, the association 243 
between serum iron and dopamine metabolism in the brain was not supported by the study data. In 244 
addition, serum iron measurements may not accurately indicate brain iron stores. There is little direct 245 
evidence to suggest that circulating iron levels reflect brain iron concentrations, although a previous 246 
magnetic resonance imaging (MRI) study showed that the proton transverse relaxation rate in brain 247 
regions is correlated with systemic iron status [60]. Therefore, our hypothesis and explanation of the 248 
data should be carefully interpreted. Further studies should consider direct measurement methods 249 
with high sensitivity and specificity to accurately assess brain iron levels [61]. Second, serum ferritin 250 
is a marker of inflammation as well as iron stores [62]. Therefore, serum ferritin levels can vary 251 
depending on various conditions, including inflammatory status. In addition, transferrin saturation 252 
calculated as the iron/TIBC ratio may not be a perfect marker of iron deficiency due to the 253 
contribution from a certain portion of non-transferrin bound iron [63]. Therefore, confounding factors 254 
must be considered in measuring circulating iron deficiency. Various markers that more precisely 255 
reflect iron status should be used in future studies. Third, iron intake was not directly measured in 256 
this study. Finally, although all of the study participants were experiencing their first episode of 257 
psychosis, the duration of psychotic illness and treatment may show an association with iron 258 
deficiency. However, the types of antipsychotics used did not differ significantly according to iron 259 
status, and the statistical significance of this result was consistent after controlling for DUP and 260 
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duration of treatment. Further longitudinal research is needed to determine the causal relationship 261 
between iron status and psychopathology.  262 
5. Conclusions 263 
We found that patients with prominent negative symptoms had significantly lower ferritin 264 
levels. Multivariate analyses adjusting for the duration of illness, depression, psychotic symptoms, 265 
social function, and other confounding variables showed that latent iron deficiency was significantly 266 
associated with negative symptoms, implying a potential relationship between iron dysfunction and 267 
negative symptoms in patients with schizophrenia spectrum disorder. The possibility of therapeutic 268 
intervention with iron should be further investigated. 269 
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